Molecular Partners Plans Workforce Reduction and Radiotherapy Focus

Company Molecular Partners Event Type Restructuring proposal and Q3 update Modality Radio-DARPin (lead-212 alpha therapy) Asset MP0712 (with Orano Med) Target DLL3 Disease Area Small-cell lung cancer Summary Molecular Partners said on 29 October that it began Swiss employee consultation on a potential reduction of…